Inhibition of human acetyl- and butyrylcholinesterase by novel carbamates of (-)- and (+)-tetrahydrofurobenzofuran and methanobenzodioxepine.
暂无分享,去创建一个
N. Greig | Qian-sheng Yu | H. Holloway | A. Brossi | D. Lahiri | A. Shafferman | D. Tweedie | D. Parrish | S. Kulkarni | Weiming Luo
[1] F. J. Luque,et al. Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease. , 2005, Journal of medicinal chemistry.
[2] N. Greig,et al. Syntheses of tetrahydrofurobenzofurans and dihydromethanobenzodioxepines from 5-hydroxy-3-methyl-3H-benzofuran-2-one. Rearrangement and ring expansion under reductive conditions on treatment with hydrides. , 2005, The Journal of organic chemistry.
[3] N. Greig,et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 2005, Current Alzheimer research.
[4] Zoran Radić,et al. In situ selection of lead compounds by click chemistry: target-guided optimization of acetylcholinesterase inhibitors. , 2005, Journal of the American Chemical Society.
[5] Hiroaki Kazui,et al. Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? , 2005, The American journal of psychiatry.
[6] S. Arnold,et al. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? , 2005, Trends in pharmacological sciences.
[7] Patrick Masson,et al. Role of water in aging of human butyrylcholinesterase inhibited by echothiophate: the crystal structure suggests two alternative mechanisms of aging. , 2005, Biochemistry.
[8] J. Becker,et al. Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition , 2005, Journal of the American Geriatrics Society.
[9] N. Greig,et al. Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. , 2004, Current pharmaceutical design.
[10] J. Raftery,et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.
[11] D. Small. Do acetylcholinesterase inhibitors boost synaptic scaling in Alzheimer's disease? , 2004, Trends in Neurosciences.
[12] N. Greig,et al. Racemic N1-norphenserine and its enantiomers: Unpredicted inhibition of human acetyl- and butyrylcholinesterase and β-amyloid precursor protein in vitro , 2003 .
[13] Yvain Nicolet,et al. Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products* , 2003, Journal of Biological Chemistry.
[14] J. Sussman,et al. A neutral molecule in a cation-binding site: specific binding of a PEG-SH to acetylcholinesterase from Torpedo californica. , 2002, Journal of molecular biology.
[15] N. Greig,et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. , 2002, Journal of medicinal chemistry.
[16] F. J. Luque,et al. 3D structure of Torpedo californica acetylcholinesterase complexed with huprine X at 2.1 A resolution: kinetic and molecular dynamic correlates. , 2002, Biochemistry.
[17] N. Greig,et al. Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action. , 2001, Journal of medicinal chemistry.
[18] H. Soreq,et al. Acetylcholinesterase — new roles for an old actor , 2001, Nature Reviews Neuroscience.
[19] N. Greig,et al. 4′-Hydroxyphenylcarbamates of (3aS)-Eseroline and (3aS)-N(1)-Noreseroline: Potential Metabolites of the Alzheimer′s Anticholinesterase Drug Phenserine. , 1999 .
[20] N. Greig,et al. Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. , 1999, Journal of medicinal chemistry.
[21] J L Sussman,et al. A preliminary comparison of structural models for catalytic intermediates of acetylcholinesterase. , 1999, Chemico-biological interactions.
[22] C. Bartolucci,et al. "Back door" opening implied by the crystal structure of a carbamoylated acetylcholinesterase. , 1999, Biochemistry.
[23] E. Perola,et al. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. , 1997, Biochimica et biophysica acta.
[24] S. Ōmura,et al. Arisugacins, selective acetylcholinesterase inhibitors of microbial origin. , 1997, Pharmacology & therapeutics.
[25] S. Lifson,et al. External and internal electrostatic potentials of cholinesterase models. , 1997, Journal of molecular graphics & modelling.
[26] J. Sussman,et al. Electrooptical measurements demonstrate a large permanent dipole moment associated with acetylcholinesterase. , 1996, Biophysical journal.
[27] J. Sussman,et al. The X-ray structure of a transition state analog complex reveals the molecular origins of the catalytic power and substrate specificity of acetylcholinesterase. , 1996 .
[28] N. Greig,et al. Phenserine and ring C hetero‐analogues: Drug candidates for the treatment of Alzheimer's disease , 1995, Medicinal research reviews.
[29] J. Sussman,et al. Three-dimensional structures of acetylcholinesterase and of its complexes with anticholinesterase agents. , 1994, Biochemical Society transactions.
[30] A. Gnatt,et al. Excavations into the active-site gorge of cholinesterases. , 1992, Trends in biochemical sciences.
[31] N. Greig,et al. Physovenines: Efficient Synthesis of (‐)‐ and (+)‐Physovenine and Synthesis of Carbamate Analogues of (‐)‐Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines. , 1991 .
[32] N. Greig,et al. Physovenines: Efficient Synthesis of (−)- and (+)-Physovenine and Synthesis of Carbarnate Analogues of (−)-Physovenine. Anticholinesterase Activity and Analgesic Properties of Optically Active Physovenines† , 1991 .
[33] A. Brossi,et al. Alfred Burger award address. Bioactive alkaloids. 4. Results of recent investigations with colchicine and physostigmine. , 1990, Journal of medicinal chemistry.
[34] J. Sufrin,et al. Steric mapping of the L-methionine binding site of ATP:L-methionine S-adenosyltransferase. , 1981, Molecular pharmacology.
[35] D. Drachman,et al. Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.
[36] J. Sussman,et al. Acetylcholinesterase , 2007, Journal of Molecular Neuroscience.
[37] N. Inestrosa,et al. Acetylcholinesterase Interaction with Alzheimer Amyloid β , 2005 .
[38] N. Inestrosa,et al. Acetylcholinesterase interaction with Alzheimer amyloid beta. , 2005, Sub-cellular biochemistry.
[39] N. Greig,et al. Novel anticholinesterases based on the molecular skeletons of furobenzofuran and methanobenzodioxepine. , 2005, Journal of medicinal chemistry.
[40] N. Viguié,et al. Engineering of a monomeric and low-glycosylated form of human butyrylcholinesterase: expression, purification, characterization and crystallization. , 2002, European journal of biochemistry.
[41] J. Cummings,et al. Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.
[42] Z. Radić,et al. Mechanism of action of cholinesterase inhibitors , 2000 .
[43] R. Schowen,et al. Transition States of Biochemical Processes , 1978, Springer US.
[44] R. Dawson. The alkaloids. , 1948, Annual review of biochemistry.